Chimeric antigen receptors targeting BCMA and methods of use thereof
AssigneeLegend Biotech USA Inc.
InventorsXiaohu Fan, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao, Dan Zhao, Xian He
Life of this patent
Estimating the term…
Abstract
Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
Claims26
An isolated nucleic acid comprising a nucleic acid sequence encoding a multivalent chimeric antigen receptor (CAR) comprising a polypeptide comprising:
- (a) an extracellular antigen binding domain comprising a first anti-BCMA binding moiety and a second BCMA binding moiety, wherein each of the first and the second anti-BCMA binding moieties is a VHH domain;
- (b) a transmembrane domain;
- and
- (c) an intracellular signaling domain,
- wherein the first BCMA binding moiety comprises
- a CDR1 comprising the amino acid sequence of SEQ ID NO:15;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:53;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:91, and the second BCMA binding moiety comprises
- a CDR1 comprising the amino acid sequence of SEQ ID NO:18;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:56;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:94.
Dependencies are inferred from the claim text.